Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evaxion ASEVAX +3.33%28 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates EVAX with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 965 Biotechnology companies, Evaxion AS ranks worse than 103626.84% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Evaxion AS's Debt-to-Equity or its related term are showing as below:
EVAX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -9.31 Med: 0.09 Max: 8.37
Current: -0.06
During the past 9 years, the highest Debt-to-Equity Ratio of Evaxion AS was 8.37. The lowest was -9.31. And the median was 0.09.
EVAX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs EVAX: -0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Evaxion AS Debt-to-Equity Related Terms
Evaxion AS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Evaxion AS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVAX vs CRVO, ALGS, TVRD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Evaxion AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evaxion AS Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evaxion AS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Evaxion AS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evaxion AS (EVAX) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Evaxion AS and its competitors. According to the industry distribution chart, Evaxion AS ranks #999999 out of 965 companies in the Biotechnology industry.
Is Evaxion AS's Debt-to-Equity too high?
Evaxion AS's current Debt-to-Equity is 0.00. Based on the distribution chart, Evaxion AS ranks #999999 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Evaxion AS has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's Debt-to-Equity compare to CRVO and ALGS?
According to the Biotechnology industry distribution chart, Evaxion AS ranks #999999 out of 965 companies for Debt-to-Equity. This places Evaxion AS in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Evaxion AS and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evaxion AS's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Evaxion AS (EVAX) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Evaxion AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Evaxion AS (EVAX), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
28GF Score
Get the complete analysis for EVAX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVAX has been successfully added to your 
